Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
154.01(c) 154.63(c) 155.59(c) 158.48(c) 156.58(c) Last
778 089 532 548 958 776 612 598 481 320 Volume
+3.85% +0.40% +0.62% +1.86% -1.20% Change
More quotes
Financials (USD)
Sales 2021 1 488 M - -
Net income 2021 -429 M - -
Net cash position 2021 2 665 M - -
P/E ratio 2021 -66,3x
Yield 2021 -
Sales 2022 2 236 M - -
Net income 2022 30,7 M - -
Net cash position 2022 2 348 M - -
P/E ratio 2022 1 154x
Yield 2022 -
Capitalization 28 416 M 28 416 M -
EV / Sales 2021 17,3x
EV / Sales 2022 11,7x
Nbr of Employees 2 092
Free-Float 99,3%
More Financials
Company
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV... 
More about the company
Ratings of Seagen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SEAGEN INC.
06/07SPRINGWORKS THERAPEUTICSá : Seagen Working Together to Study Multiple Myeloma Co..
MT
06/03SEAGENá : Announces Long-Term Results from TUKYSA« (tucatinib) Pivotal Trial in ..
BU
06/02SEAGENá : to Present at the Goldman Sachs 42nd Annual Global Healthcare Conferen..
BU
05/20ASTELLAS PHARMAá : and Seagen Announce Updated Results from Two Trials of PADCEV..
AQ
05/20SEZARY SYNDROME PIPELINE : Emerging Therapies and Key pharma players involved by..
AQ
05/19SEAGEN INC.á : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/18INSIDER TRENDS : Seagen Insider Receives Stock Award and Converts/Exercises Deri..
MT
05/18Astellas to Present Data from Expanding Oncology Portfolio During the 2021 AS..
AQ
05/17SEAGENá : Evercore ISI Initiates Coverage on Seagen With In-Line Rating, $153 Pr..
MT
05/13INSIDER TRENDS : Insider Sale at Seagen Slowing 90-Days of Buying
MT
04/30SEAGENá : Berenberg Bank Adjusts Seagen PT to $197 From $208, Maintains Buy Rati..
MT
04/30SEAGENá : Oppenheimer Adjusts Seagen PT to $208 From $213, Maintains Outperform ..
MT
04/30SEAGENá : Piper Sandler Adjusts Seagen's Price Target to $160 From $170, Maintai..
MT
04/30SEAGENá : Credit Suisse Lowers Seagen's PT to $141 from $145 After In Line Q1 Re..
MT
04/30SEAGENá : RBC Capital Adjusts Seagen PT to $148 From $169 Following Dissapointin..
MT
More news
News in other languages on SEAGEN INC.
2020US-Konzern Merck & Co übernimmt Krebsforscher Velosbio
202010 Biotechs qui font parler d'elles
2020Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
2020Aktien New York: Übernahme-Welle sorgt für einen starken Wochenauftakt
2020DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 14.09.2020 - 15.15 Uhr
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 185,89 $
Last Close Price 156,58 $
Spread / Highest target 62,2%
Spread / Average Target 18,7%
Spread / Lowest Target -8,67%
EPS Revisions
Managers and Directors
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SEAGEN INC.-10.60%28 416
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
HANGZHOU TIGERMED CONSULTING CO., LTD13.85%24 128